Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Unicycive Therapeutics (UNCY) Preferred Shares Issued (2023 - 2024)

Unicycive Therapeutics filings provide 2 years of Preferred Shares Issued readings, the most recent being $50.0 million for Q1 2024.

On a quarterly basis, Preferred Shares Issued rose 65.62% to $50.0 million in Q1 2024 year-over-year; TTM through Dec 2024 was $50.0 million, a 65.62% increase, with the full-year FY2024 number at $50.0 million, up 65.62% from a year prior.
Preferred Shares Issued hit $50.0 million in Q1 2024 for Unicycive Therapeutics, up from $30.2 million in the prior quarter.
In the past five years, Preferred Shares Issued ranged from a high of $50.0 million in Q1 2024 to a low of $30.2 million in Q1 2023.